The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: A dual [11C]raclopride and [18 F]FDG imaging study with aripiprazole

Psychopharmacology

Volumn 227, Issue 2, 2013, Pages 221-229

  Kim, Euitae ^a,b,c   Howes, Oliver D ^b,c   Turkheimer, Federico E ^c   Kim, Bo Hyung ^a   Jeong, Jae Min ^a   Kim, Ji Who ^a   Lee, Jae Sung ^a   Jang, In Jin ^a   Shin, Sang Goo ^a   Kapur, Shitij ^c   Kwon, Jun Soo ^a  

^a Seoul National University   (South Korea)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aripiprazole; Fluorodeoxyglucose F18; Positron emission tomography; Raclopride C11; Working memory

Indexed keywords

ARIPIPRAZOLE; BIOLOGICAL MARKER; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; RACLOPRIDE C 11; CARBON; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; RACLOPRIDE;

ARTICLE; BRAIN FUNCTION; BRAIN METABOLISM; COGNITION; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAM; FRONTAL LOBE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGE DISPLAY; MALE; NERVE STIMULATION; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WORKING MEMORY; ADULT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SHORT TERM MEMORY; SINGLE BLIND PROCEDURE;

ADULT; ANTIPSYCHOTIC AGENTS; CARBON RADIOISOTOPES; COGNITION; CORPUS STRIATUM; FLUORODEOXYGLUCOSE F18; FRONTAL LOBE; HUMANS; MALE; MEMORY, SHORT-TERM; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; QUINOLONES; RACLOPRIDE; REACTION TIME; RECEPTORS, DOPAMINE D2; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84879600947     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2953-0     Document Type: Article

References (52)

1. Barch DM, Smith E (2008) The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia. Biol Psychiatry 64:11-17
2. Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmayer JP, Rusinek H, Wolkin A, Cancro R, Schiffer W (1998) Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry 155:337-343
3. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979) Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205:929-932
4. Buchsbaum MS, Haznedar MM, Aronowitz J, Brickman AM, Newmark RE, Bloom R, Brand J, Goldstein KE, Heath D, Starson M, Hazlett EA (2007) FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophr Res 94:293-305
5. Calzavara R, Mailly P, Haber SN (2007) Relationship between the corticostriatal terminals from areas 9 and 46, and those from area 8A, dorsal and rostral premotor cortex and area 24c: an anatomical substrate for cognition to action. Eur J Neurosci 26:2005-2024
6. Castner SA, Goldman-Rakic PS, Williams GV (2004) Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) 174:111-125
7. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486
8. Eblen F, Graybiel AM (1995) Highly restricted origin of prefrontal cortical inputs to striosomes in the macaque monkey. J Neurosci 15:5999-6013
9. First MB, Spitzer RL, Miriam G, Williams BWJ (2002) Structured clinical interview for DSM-IV-TR axis I disorders, Research version, Non-patient edition. (SCID-I/NP). Biometrics Research, New York State Psychiatry Institute, New York
10. Frankle WG, Laruelle M, Haber SN (2006) Prefrontal cortical projections to the midbrain in primates: evidence for a sparse connection. Neuropsychopharmacology 31:1627-1636
11. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Grasby PM, McGuire PK (2010) Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 67:683-691
12. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P (2011) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16:67-75
13. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV (2004) Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174:3-16
14. Hirose T, Kikuchi T (2005) Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest 52(Suppl):284-290
15. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray R, McGuire P (2011a) Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 16:885-886
16. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P (2011b) Dopamine synthesis capacity before onset of psychosis: a prospective [18 F]-DOPA PET imaging study. Am J Psychiatry 168:1311-1317
17. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S (2009a) Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 15:2550-2559
18. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776-786
19. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 35:549-562
20. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009b) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66:13-20
21. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L (1998) Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 18:941-950
22. Ito H, Takahashi H, Arakawa R, Takano H, Suhara T (2008) Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. NeuroImage 39:555-565
23. Jaeggi SM, Buschkuehl M, Perrig WJ, Meier B (2010) The concurrent validity of the N-back task as a working memory measure. Memory 18:394-412
24. Kang KW, Lee DS, Cho JH, Lee JS, Yeo JS, Lee SK, Chung JK, Lee MC (2001) Quantification of F-18 FDG PET images in temporal lobe epilepsy patients using probabilistic brain atlas. NeuroImage 14:1-6
25. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325-337
26. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201-222
27. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18 F]fallypride. Neuropsychopharmacology 33:3111-3125
28. Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, Moore H, Kandel ER (2006) Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49:603-615
29. Kim E, Howes OD, Kim BH, Jeong JM, Lee JS, Jang IJ, Shin SG, Turkheimer FE, Kapur S, Kwon JS (2012) Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. J Cereb Blood Flow Metab 32:759-768
30. Kim E, Kwon JS, Shin YW, Lee JS, Kang WJ, Jo HJ, Lee JM, Yu KS, Kang DH, Cho JY, Jang IJ, Shin SG (2008) Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. Pharmacogenet Genomics 18:91-97
31. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. NeuroImage 4:153-158
32. Lane CJ, Ngan ET, Yatham LN, Ruth TJ, Liddle PF (2004) Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia. J Psychiatry Neurosci 29:30-37
33. Lee JS, Lee DS (2005) Analysis of functional brain images using population-based probabilistic atlas. Curr Med Imaging Rev 1:81-87
34. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-747
35. Magistretti PJ, Pellerin L (1996) The contribution of astrocytes to the 18 F-2-deoxyglucose signal in PET activation studies. Mol Psychiatry 1:445-452
36. Magistretti PJ, Pellerin L (1999) Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 354:1155-1163
37. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5:267-271
38. Molina V, Gispert JD, Reig S, Pascau J, Martinez R, Sanz J, Palomo T, Desco M (2005a) Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. Int Clin Psychopharmacol 20:13-18
39. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, Desco M, Palomo T (2005b) Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl) 178:17-26
40. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, Palomo T, Desco M (2003) Cerebral metabolism and risperidone treatment in schizophrenia. Schizophr Res 60:1-7
41. Ngan ET, Lane CJ, Ruth TJ, Liddle PF (2002) Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change. J Neurol Neurosurg Psychiatry 72:106-110
42. Nyberg S, Olsson H, Nilsson U, Maehlum E, Halldin C, Farde L (2002) Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 162:37-41
43. Olsson H, Farde L (2001) Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - a simulation study based on experimental data. NeuroImage 14:936-945
44. Owen AM, McMillan KM, Laird AR, Bullmore E (2005) N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp 25:46-59
45. Potkin SG, Buchsbaum MS, Jin Y, Tang C, Telford J, Friedman G, Lottenberg S, Najafi A, Gulasekaram B, Costa J et al (1994) Clozapine effects on glucose metabolic rate in striatum and frontal cortex. J Clin Psychiatry 55(B):63-66
46. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690
47. Reep RL, Cheatwood JL, Corwin JV (2003) The associative striatum: organization of cortical projections to the dorsocentral striatum in rats. J Comp Neurol 467:271-292
48. Schlagenhauf F, Dinges M, Beck A, Wustenberg T, Friedel E, Dembler T, Sarkar R, Wrase J, Gallinat J, Juckel G, Heinz A (2010) Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophr Res 118:189-200
49. Simpson EH, Kellendonk C, Kandel E (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65:585-596
50. Suzuki H, Gen K, Inoue Y (2011) An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35:161-168
51. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF (2007) Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 10:376-384
52. Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S (2012) Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol 26:806-812